Pfizer: to supply the EU with 200 million doses of vaccine
(CercleFinance.com) - Pfizer and BioNTech said that they have reached an agreement with the European Commission to supply 200 million doses of their experimental vaccine candidate against Covid-19 to European Union member states.
The deal includes an option for the European Commission to request an additional 100 million doses, the two drugmakers said.
Deliveries are expected to start by the end of 2020, if the investigational vaccine receives approval from the European Medicines Agency (EMA).
Vaccine doses for Europe will be produced in BioNTech's German manufacturing sites, as well as in Pfizer's plant in Belgium, the companies said.
The deal comes alongside contracts already signed with AstraZeneca, Sanofi-GSK and Janssen, and successful exploratory talks with CureVac and Moderna, the EU said.
"This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective," the Commission said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The deal includes an option for the European Commission to request an additional 100 million doses, the two drugmakers said.
Deliveries are expected to start by the end of 2020, if the investigational vaccine receives approval from the European Medicines Agency (EMA).
Vaccine doses for Europe will be produced in BioNTech's German manufacturing sites, as well as in Pfizer's plant in Belgium, the companies said.
The deal comes alongside contracts already signed with AstraZeneca, Sanofi-GSK and Janssen, and successful exploratory talks with CureVac and Moderna, the EU said.
"This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective," the Commission said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.